Red Tape Slashed to Ramp Up U.S. Critical Medicine Factories
Published Date: 5/8/2025
Presidential Document
Summary
This new order helps American medicine makers speed up building and upgrading factories by cutting red tape and easing inspections. It’s designed to boost the local production of important medicines, making sure we’re ready for health emergencies and less dependent on other countries. These changes start right away and aim to save time and money, helping Americans get critical medicines faster and safer.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
5 provisions identified: 4 benefits, 0 costs, 1 mixed.
FDA streamlines manufacturing review
Within 180 days of May 5, 2025, the FDA must review regulations and guidance that apply to developing domestic pharmaceutical manufacturing and take steps to eliminate duplicative or unnecessary requirements, make reviews more timely and predictable, and accelerate development of new or expanded facilities. The FDA will evaluate its inspection approach, expand early technical advice programs, improve enforcement of data reporting under 21 U.S.C. 360(j)(3), and provide clearer guidance for site changes including moving production from foreign to domestic facilities.
EPA updates permitting rules
Within 180 days of May 5, 2025, the Environmental Protection Agency must update regulations and guidance that apply to inspection and approval of new and expanded pharmaceutical manufacturing capacity to eliminate duplicative or unnecessary requirements and improve timeliness and predictability of agency review. The EPA is also designated the lead agency for NEPA Environmental Impact Statements for pharmaceutical manufacturing facilities unless another agency assumes that role.
Single point of contact for permits
The lead agency for NEPA reviews must designate a single point of contact to coordinate with permit applicants, and the Office of Management and Budget will coordinate with that lead to expedite permit review and approval for pharmaceutical manufacturing projects. This coordination is directed under the order issued May 5, 2025.
Army Corps to reassess water permits
Within 180 days of May 5, 2025, the Secretary of the Army, through the Assistant Secretary of the Army for Civil Works, must review nationwide permits issued under section 404 of the Clean Water Act and section 10 of the Rivers and Harbors Appropriation Act to determine whether an activity-specific nationwide permit is needed to facilitate permitting of pharmaceutical manufacturing facilities.
More foreign facility inspections; fees
Within 90 days of May 5, 2025, the FDA must develop improvements to its risk-based inspection regime to ensure routine reviews of overseas manufacturing facilities that supply U.S. medicines; these reviews are to be funded by increased fees on foreign manufacturing facilities to the extent consistent with law. The FDA must also publicly disclose the annual number of inspections of such foreign facilities with detail by country and by manufacturer.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in